| _version_ | 1866901724652896256 |
|---|---|
| author | Shivcharan Kamble*, Rashee Shahu, Sunita Kode, Tejaswini Gaikwad, Pooja Rasal |
| author_facet | Shivcharan Kamble*, Rashee Shahu, Sunita Kode, Tejaswini Gaikwad, Pooja Rasal |
| contents | <p><span>SGLT2s are a new type of oral diabetes treatment that work by preventing glucose from being absorbed through the kidneys, which helps the body get rid of extra glucose through the urine. Unlike traditional ways to treat diabetes, SGLT2 inhibitors work without using insulin, so people taking this type of medicine can manage their blood sugar levels with less chance of developing low blood sugar (hypoglycemia). SGLT2 inhibitors also may help people lose a small amount of weight and maintain lower blood pressure. The benefits of taking SGLT2 inhibitors go beyond just controlling blood sugar levels. Clinical studies are showing that SGLT2 inhibitors help protect the heart and kidneys. In fact, large studies of patients with heart failure have found that SGLT2 inhibitors reduce the risk of being hospitalized for heart failure; slow down the progression of chronic kidney disease; and lower the risk of dying from cardiovascular causes, even in people who do not have diabetes. The additional benefits of taking SGLT2 inhibitors may be due to blood flow changes throughout the body, including the way the heart works, how the body metabolizes food, and how inflammation occurs in the body. Although SGLT2 inhibitors can cause unwanted effects (such as infections in the genital area or very rarely euglycemic diabetic ketoacidosis), the overall benefits of taking SGLT2 inhibitors greatly outweigh the risks if the right patients are chosen and monitored closely. This expanding role for SGLT2 inhibitors in combination with other medications (for example, when treating patients with diabetes, high blood pressure, and/or high cholesterol) makes them very important in providing integrated care across the cardio-renal-metabolic spectrum</span><span>.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18322823 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | SGLT2 Inhibitors: Pharmacology and Expanding Role Beyond Diabetes Shivcharan Kamble*, Rashee Shahu, Sunita Kode, Tejaswini Gaikwad, Pooja Rasal SGLT2 Inhibitor, Diabetes Mellites, Heart Attack, Protection, Weight Loss <p><span>SGLT2s are a new type of oral diabetes treatment that work by preventing glucose from being absorbed through the kidneys, which helps the body get rid of extra glucose through the urine. Unlike traditional ways to treat diabetes, SGLT2 inhibitors work without using insulin, so people taking this type of medicine can manage their blood sugar levels with less chance of developing low blood sugar (hypoglycemia). SGLT2 inhibitors also may help people lose a small amount of weight and maintain lower blood pressure. The benefits of taking SGLT2 inhibitors go beyond just controlling blood sugar levels. Clinical studies are showing that SGLT2 inhibitors help protect the heart and kidneys. In fact, large studies of patients with heart failure have found that SGLT2 inhibitors reduce the risk of being hospitalized for heart failure; slow down the progression of chronic kidney disease; and lower the risk of dying from cardiovascular causes, even in people who do not have diabetes. The additional benefits of taking SGLT2 inhibitors may be due to blood flow changes throughout the body, including the way the heart works, how the body metabolizes food, and how inflammation occurs in the body. Although SGLT2 inhibitors can cause unwanted effects (such as infections in the genital area or very rarely euglycemic diabetic ketoacidosis), the overall benefits of taking SGLT2 inhibitors greatly outweigh the risks if the right patients are chosen and monitored closely. This expanding role for SGLT2 inhibitors in combination with other medications (for example, when treating patients with diabetes, high blood pressure, and/or high cholesterol) makes them very important in providing integrated care across the cardio-renal-metabolic spectrum</span><span>.</span></p> |
| title | SGLT2 Inhibitors: Pharmacology and Expanding Role Beyond Diabetes |
| topic | SGLT2 Inhibitor, Diabetes Mellites, Heart Attack, Protection, Weight Loss |
| url | https://doi.org/10.5281/zenodo.18322823 |